14th Mar 2016 11:09
LONDON (Alliance News) - GW Pharmaceuticals PLC on Monday announced positive results from its phase III study of epidiolex in Dravet syndrome, a rare form of epilepsy.
GW Pharmaceuticals said it achieved its primary endpoint in the study of a "significant reduction" in convulsive seizures compared with a placebo.
Epidiolex has both an orphan drug designation, and a fast designation from the US Food and Drug Administration in the treatment of Dravet syndrome.
"The positive outcome of this Phase 3 trial is a significant milestone in the development of Epidiolex as a potential new treatment for patients suffering from Dravet syndrome. We are excited about the potential for Epidiolex to become the first FDA approved treatment option specifically for Dravet syndrome patients and their families," said Chief Executive Officer Justin Gover in a statement.
Shares in GW Pharmaceuticals were up 37% at 296.50 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L